Skip to main content

Table 3 Incremental results for the base case cost-effectiveness analysis for IND/GLY versus SFC

From: Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

Outcomes

Time horizon (years)

IND/GLY

SFC

Incremental (IND/GLY-SFC)

QALYs (per patient)

1

0.617

0.615

0.002

5

2.513

2.495

0.018

10

4.102

4.054

0.047

Lifetime

5.653

5.520

0.134

LYs (per patient)

1

0.979

0.979

0.000

5

4.132

4.117

0.015

10

6.780

6.726

0.055

Lifetime

9.328

9.137

0.192

Total costs (€)(per patient)a

1

5406

5621

−214

5

29,486

30,620

−1134

10

50,062

51,716

−1654

Lifetime

68,406

69,618

−1211

  1. IND/GLY indacaterol/glycopyrronium, LYs life-years, QALYs quality-adjusted life-years, SFC salmeterol/fluticasone
  2. aNegative numbers indicate cost savings (e.g., IND/GLY results in savings of €1654 per patient over a time horizon of 10 years compared to SFC)